BACKGROUND: CD90(+) prostate cancer-associated (CP) stromal cells represent a diseased cell type found only in tumor tissue. They differ from their normal counterpart in gene expression and inductive signaling. Genetic reprogramming by induced pluripotent stem (iPS) cell technology can effectively change adult cells into stem-like cells through wholesale alteration of the gene expression program. This technology might be used to 'erase' the abnormal gene expression of diseased cells. The resultant iPS cells would no longer express the disease phenotype, and behave like stem cells. METHODS: CP stromal cells, isolated from tumor tissue of a surgically resected prostate by anti-CD90-mediated sorting and cultured in vitro, were transfected with in vitro packaged lentiviral expression vectors containing stem cell transcription factor genes POU5F1, LIN28, NANOG, and SOX2. RESULTS: Alkaline phosphatase-positive iPS cells were obtained in about 3 weeks post-transfection at a frequency of 10(-4) . Their colony morphology was indistinguishable from that of human embryonic stem (ES) cells. Transcriptome analysis showed a virtually complete match in gene expression between the iPS and ES cells. CONCLUSIONS: Genes of CP stromal cells could be fully inactivated by genetic reprogramming. As a consequence, the disease phenotype was 'cured'.
BACKGROUND: CD90(+) prostate cancer-associated (CP) stromal cells represent a diseased cell type found only in tumor tissue. They differ from their normal counterpart in gene expression and inductive signaling. Genetic reprogramming by induced pluripotent stem (iPS) cell technology can effectively change adult cells into stem-like cells through wholesale alteration of the gene expression program. This technology might be used to 'erase' the abnormal gene expression of diseased cells. The resultant iPS cells would no longer express the disease phenotype, and behave like stem cells. METHODS: CP stromal cells, isolated from tumor tissue of a surgically resected prostate by anti-CD90-mediated sorting and cultured in vitro, were transfected with in vitro packaged lentiviral expression vectors containing stem cell transcription factor genes POU5F1, LIN28, NANOG, and SOX2. RESULTS: Alkaline phosphatase-positive iPS cells were obtained in about 3 weeks post-transfection at a frequency of 10(-4) . Their colony morphology was indistinguishable from that of human embryonic stem (ES) cells. Transcriptome analysis showed a virtually complete match in gene expression between the iPS and ES cells. CONCLUSIONS: Genes of CP stromal cells could be fully inactivated by genetic reprogramming. As a consequence, the disease phenotype was 'cured'.
Authors: Julia Shih; Munira Rahman; Quang T Luong; Shirley H Lomeli; Joseph Riss; Robert M Prins; Ali O Gure; Gang Zeng Journal: Am J Clin Exp Immunol Date: 2014-08-15
Authors: Gisely T Borges; Eneida F Vêncio; Ricardo Z N Vêncio; Robert L Vessella; Carol B Ware; Alvin Y Liu Journal: Curr Urol Rep Date: 2015-01 Impact factor: 3.092
Authors: Ramakumar Tummala; Nagalakshmi Nadiminty; Wei Lou; Yezi Zhu; Regina Gandour-Edwards; Hong-Wu Chen; Christopher P Evans; Allen C Gao Journal: Am J Pathol Date: 2013-07 Impact factor: 4.307
Authors: Michael Lattanzi; Yesung Lee; Danny Simpson; Una Moran; Farbod Darvishian; Randie H Kim; Eva Hernando; David Polsky; Doug Hanniford; Richard Shapiro; Russell Berman; Anna C Pavlick; Melissa A Wilson; Tomas Kirchhoff; Jeffrey S Weber; Judy Zhong; Iman Osman Journal: J Natl Cancer Inst Date: 2019-02-01 Impact factor: 13.506
Authors: Sara S Franco; Karolina Szczesna; Maria S Iliou; Mohammed Al-Qahtani; Ali Mobasheri; Julianna Kobolák; András Dinnyés Journal: BMC Cancer Date: 2016-09-30 Impact factor: 4.430
Authors: Hongjuan Zhao; Ning Sun; Sarah R Young; Rosalie Nolley; Jennifer Santos; Joseph C Wu; Donna M Peehl Journal: PLoS One Date: 2013-05-22 Impact factor: 3.240
Authors: Emma Borrego-Diaz; Benjamin C Powers; Vugar Azizov; Scott Lovell; Ruben Reyes; Bradley Chapman; Ossama Tawfik; Douglas McGregor; Francisco J Diaz; Xinkun Wang; Peter Van Veldhuizen Journal: Int J Oncol Date: 2014-09-09 Impact factor: 5.650
Authors: Elizabeth A Vitello; Sue-Ing Quek; Heather Kincaid; Thomas Fuchs; Daniel J Crichton; Pamela Troisch; Alvin Y Liu Journal: Oncotarget Date: 2016-08-02